Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients With Stage II-III Colorectal Cancer

NCT06654622 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06654622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06654622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients With Stage II-III Colorectal Cancer
Lead sponsor
City of Hope Medical Center
Phase
Observational
Overall status
Completed
Start date
April 1, 2023
Completion date
February 18, 2026
Enrollment
175 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colo-rectal cancer, colorectal cancer recurrent